(3-吡啶甲氧基)胺 | 37832-20-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: (3-吡啶甲氧基)胺
• 中文别名: O-[(3-吡啶基)甲基]羟胺
• 英文名称: O-(pyridin-3-ylmethyl)hydroxylamine
• 英文别名: O-[(3-Pyridyl)methyl]hydroxylamine
• CAS: 37832-20-5
• 化学式: C₆H₈N₂O
• mdl: MFCD13175304
• 分子量: 124.142
• InChiKey: TVPSRTVMZGECAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3-吡啶甲氧基)胺 在 盐酸 作用下， 以 乙醇 为溶剂， 反应 72.0h， 生成 O-(Pyridin-3-ylmethyl)hydroxylamine;hydrochloride
  参考文献：
  名称：

  Synthesis and Fungicidal Activity of Macrolactams and Macrolactones with an Oxime Ether Side Chain

  摘要：

  Three series of novel macrolactams and macrolactones - 12-alkoxyimino-tetradecanlactam, 12-alkoxyiminopentadecanlactam, and 12-alkoxyiminodecanlactone derivatives (7A, 7B, and 7C) - were synthesized from corresponding 12-oxomacrolactams and 12-oxomacrolactone. Their structures were confirmed by H-1 NMR and elemental analysis. The Z and E isomers of 7A and 7B were separated, and their configurations were determined by H-1 NMR. These compounds showed fair to excellent fungicidal activities against Rhizoctonia solani Kuhn. It is interesting that the Z and E isomers of most of the compounds have quite different fungicidal activities. The fact that the compounds have a gradual increase of fungicidal activity in the order of 7A, 7C, and 7B indicated that the macrocyclic derivatives with a hydrogen-bonding acceptor (=N-O-) and a hydrogen-bonding donor (-CONH-) on the ring, and a three methylenes distance (CH2CH2CH2) between these two functional groups, exhibited the best fungicidal activity. The bioassay also showed that 7B not only has good fungicidal activity but also may have a broad spectrum of fungicidal activities.

  DOI：

  10.1021/jf072733+
• 作为产物：
  描述：

  N-pyridin-3-ylmethoxy-phthalimide 在 一水合肼 作用下， 以 乙醇 为溶剂， 生成 (3-吡啶甲氧基)胺
  参考文献：
  名称：

  用于聚糖选择性自由基和酸碱化学的仿生试剂：通过质谱法测定聚糖结构的应用

  摘要：

  大自然擅长将聚糖分解成它们的成分，通常是通过酶促酸碱催化来实现糖苷键的选择性裂解。注意到质子转移在许多这些酶的活性位点中的重要性，我们描述了一种用于酸催化聚糖测序 (PRAGS) 的隔离质子试剂，该试剂使用具有中等质子亲和力的吡啶部分衍生化聚糖的还原末端。PRAGS 衍生聚糖的气相碰撞活化主要产生 C1-O 糖苷键裂解，保留还原末端的电荷。可以分析由此产生的系统性 PRAGS 指导的聚糖解构，以提取聚糖组成和序列。聚糖也很容易被自由基解离，主要是活性氧，这启发了我们开发自由基活化聚糖测序 (FRAGS) 试剂，该试剂将自由基前体与吡啶部分结合，可与目标聚糖的还原末端偶联。FRAGS 衍生聚糖的碰撞活化产生自由基，该自由基反应产生大量交叉环裂解、糖苷键裂解以及这些类型裂解的组合，并在还原端保留电荷。使用 FRAGS 试剂通过仅在这些位置观察到的特定碎片模式来识别分支位点。研究和讨论了解离机制

  DOI：

  10.1021/ja402810t

文献信息

• [EN] 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS DPP-IV INHIBITORS<br/>[FR] DERIVES 2-CYANOPYRROLIDINE ET LEUR UTILISATION COMME INHIBITEURS DE LA DPP-IV
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2004099185A1

  公开（公告）日：2004-11-18

  A compound of the formula (I) or a pharmaceutically acceptable salt thereof: [wherein X is CFH, or CF?2#191, R1 is the moiety represented by the formula: [wherein R2 is (lower)alkyl, R3 is phenyl-(lower)alkyl, and the like.], and the like.] Compounds of formula (I) inhibit DPP-IV activity. They are therefore useful in the treatment of conditions mediated by DPP-IV, such as NIDDM.

  化合物的结构式（I）或其药学上可接受的盐：[其中X为CFH，或CF?2＃191，R1为由以下结构式表示的基团：[其中R2为（较低）烷基，R3为苯基-（较低）烷基等。]，等等。] 公式（I）的化合物抑制DPP-IV活性。因此，它们在治疗由DPP-IV介导的疾病，如NIDDM中是有用的。
• Mandelic acid derivatives and their use as throbin inhibitors
  申请人：——

  公开号：US20040019033A1

  公开（公告）日：2004-01-29

  There is provided a compound of formula I 1 wherein R a , R 1 , R 2 , Y and R 3 have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

  提供了一种公式I的化合物 1 其中R a , R 1 , R 2 , Y和R 3 具有说明书中给出的含义以及药学上可接受的衍生物（包括前药），这些化合物和衍生物可用作竞争性胰蛋白酶样蛋白酶抑制剂，如凝血酶，因此，特别是用于需要抑制凝血酶的情况（例如血栓形成）或作为抗凝剂。
• INHIBITORS OF FLAVIVIRIDAE VIRUSES
  申请人：CANALES Eda

  公开号：US20110178058A1

  公开（公告）日：2011-07-21

  Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

  提供的是I式化合物： 及其药用可接受的盐和酯。所提供的化合物、组合物和方法对于治疗黄病毒科病毒感染，特别是丙型肝炎感染，是有用的。
• [EN] OXIM DERIVATIVES AS HSP90 INHIBITORS<br/>[FR] DÉRIVÉS D'OXIME EN TANT QU'INHIBITEURS DE HSP90
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2009097578A1

  公开（公告）日：2009-08-06

  The invention relates to HSP90 inhibiting compounds consisting of the formula: (I) wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  本发明涉及具有式(I)结构的HSP90抑制化合物，其中变量如本文所定义。本发明还涉及包含此类化合物的药物组合物、套件和制造品；制备这些化合物的方法和中间体；以及使用这些化合物的方法。
• [EN] PHARMACEUTICAL COMBINATION<br/>[FR] COMBINAISON PHARMACEUTIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2003101956A1

  公开（公告）日：2003-12-11

  There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.

  提供了一种组合产品，包括：(1) WO 02/44145中权利要求1的化合物或WO 02/44145中权利要求20的化合物（或其衍生物）或药用可接受的衍生物；以及（1）WO 01/28992中权利要求1定义的化合物或（2）WO 01/28992中权利要求34的化合物或（3）化合物A或B或C或D（或药用可接受的盐）用于治疗心律不齐或其凝血控制的并发症。